Compare Merck & Co., Inc. (MRK) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Match Group Inc — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while Match Group Inc trades at $41.46 (market cap $9.51B). The key difference: Merck & Co., Inc. is far larger — about 38.3× Match Group Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.3%). Which is the better fit depends on your goals.
| MRK | MTCH | |
|---|---|---|
Market Cap | $363.98B | $9.51B |
Sector | Health | Media |
52-Week High | $156.43 | $42.44 |
52-Week Low | $77.60 | $28.90 |
Enterprise Value | $410.75B | $12.48B |
Dividend Yield | 2.3% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
MTCH trades at $41.15, down 1.7% today, near its consensus price target of $42.50. The stock shows a bullish technical signal with support at $41 and resistance at $42. Recent earnings beat expectations in Q2 2026, with Q3 2026 results pending. Revenue stability around $3.5B and a net income margin of 20.17% reflect solid profitability, though high debt levels pose a risk. Analysts are overwhelmingly positive with 53% buy ratings and no sell recommendations.
The outlook for MTCH is cautiously optimistic, driven by product innovation at Tinder and strong cash flow growth. Investment opportunities include potential upside to the $45 high price target and dividend payments. Risks include elevated long-term debt of $3.85B and competitive pressures in the dating app market. Investors should monitor Q3 2026 earnings for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
